Paper Details

  1. Home
  2. Paper Details

[Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].

Author: AktasO, HartungH-P, MeuthS G, RuckT

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review summarizes the clinical study data on oral cladribine tablets (Mavenclad®) for relapsing-remitting multiple sclerosis (RMS). Cladribine tablets are administered during two short treatment phases of 8-10 days with a 1-year interval. The drug selectively reduces the number of T and B lymphocytes, resulting in a pronounced and sustained effect on MS disease activity.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The selective modulation of lymphocyte numbers and function is an attractive concept in the treatment of relapsing-remitting multiple sclerosis (RMS). OBJECTIVE: Cladribine tablets (Mavenclad®), an oral RMS medication with an innovative treatment concept, have been available since Augus...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00115-018-0498-0

データ提供：米国国立医学図書館（NLM）

Cladribine Tablets: A New Dawn for Relapsing-Remitting Multiple Sclerosis (RMS) Treatment

This research delves into the fascinating world of oral immunotherapy for relapsing-remitting multiple sclerosis (RMS), a chronic and often debilitating neurological disorder. It's like discovering a hidden oasis of hope in the vast desert of RMS research, offering a new treatment option for patients. The study focuses on cladribine tablets, a medication with a unique approach to managing RMS. The researchers explore the clinical data surrounding cladribine tablets and their potential use in treating patients with RMS.

Cladribine Tablets: A Promising Approach for RMS Treatment

Cladribine tablets provide a sustained and strong reduction in RMS disease activity, offering a potential respite from the relentless challenges of this neurological disorder. It's like finding a steady stream in the midst of a desert, offering a source of relief and stability. The study highlights the importance of regular monitoring and responsible contraception during treatment, ensuring a safe and effective path for patients.

Improving the Lives of RMS Patients: A New Era of Treatment

This research paves the way for a new era of treatment for RMS patients, offering a glimmer of hope in the vast desert of their condition. It's like discovering a new path leading to a healthier future, one with less disease activity and greater quality of life. Cladribine tablets represent a significant advancement in the fight against RMS, offering a patient-friendly and effective treatment option.

Dr.Camel's Conclusion

This study offers a promising new path in the treatment of RMS, one that's not only effective but also convenient and well-tolerated. It's like discovering a rare desert flower, blooming amidst the challenges of the disease. Cladribine tablets hold the potential to improve the lives of many RMS patients, bringing hope and relief to a previously challenging landscape.
Date :
  1. Date Completed 2019-08-12
  2. Date Revised 2019-08-12
Further Info :

Pubmed ID

29523912

DOI: Digital Object Identifier

10.1007/s00115-018-0498-0

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.